A novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture

Si Yuan Pan*, Zhan Hong Jia, Yi Zhang, Qing Yu, Xiao Yan Wang, Nan Sun, Pei Li Zhu, Zhiling YU, Kam Ming Ko

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Hyperlipidemia is referred to as hypercholesterolemia, hypertriglyceridemia, or both in combined hyperlipidemia. Here, a novel mouse model of combined hyperlipidemia is described. Mice were orally given a single dose of a modeling agent (MA) made of a mixture of schisandrin B/cholesterol/bile salts (1/2/0.5 g/kg) suspended in olive oil. MA treatment increased serum triglycerides (TG) and total cholesterol (TC) (up to 422% and 100% at 12 - 96 h post-treatment, respectively) and hepatic TG and TC (up to 220% and 26%, respectively) in a time- and dose-dependent manner, associated with elevation of high-density lipoprotein and low-density lipoprotein levels. Serum alanine/aspartate aminotransferase activities, indicators of liver cell damage, were also elevated (up to 198%) at 48 and 72 h post-MA treatment. Fenofibrate blocks MA-induced hyperlipidemia, lipid accumulation in the liver, as well as liver injury. Oral administration of a mixture of schisandrin B, cholesterol, and bile salt could generate an interesting mouse model of combined hyperlipidemia associated with hepatic steatosis and steatohepatitis.

Original languageEnglish
Pages (from-to)110-119
Number of pages10
JournalJournal of Pharmacological Sciences
Volume123
Issue number2
DOIs
Publication statusPublished - 2013

Scopus Subject Areas

  • Molecular Medicine
  • Pharmacology

User-Defined Keywords

  • Combined hyerlipidemia
  • Fenofibrate
  • Hepatic steatosis
  • Hepatomegaly
  • Schisandrin B

Fingerprint

Dive into the research topics of 'A novel mouse model of combined hyperlipidemia associated with steatosis and liver injury by a single-dose intragastric administration of schisandrin B/cholesterol/bile salts mixture'. Together they form a unique fingerprint.

Cite this